RVMD (Revolution Medicines Inc) Cumulative Company Assets

Official company branding of Revolution Medicines Inc (RVMD)

Revolution Medicines faces a lack of sales and high research costs, which creates risks for its capital. Analyzing the company's overall resource structure in GURU.Markets, we see that 3376.53 is the current level of the indicator. The drug discovery process is accelerating through the implementation of robotic screening systems. Meanwhile, its unique platform for blocking RAS protein mutations provides access to a colossal oncology market.

Revolution Medicines Inc (RVMD) Aggregate Company Assets: for the period 07/04/2022 - 10/31/2026

Financial and market metric breakdowns for RevMed (RVMD)

- stock quotes and analyst forecast:
Share Price revmed.com|RVMD - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Revolution Medicines Corp|RVMD - Enterprise Value
- company book value details:
Book Value per Share Revolution Medicines|RVMD - Company Book Value|Capitalization to Book Value Ratio revmed.com|RVMD - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Revolution Medicines|RVMD - Long-Term Debt to Capital|Current Liabilities to Capital Revolution Medicines Corp|RVMD - Company Debts|Debt to Net Assets Ratio Revolution Medicines Corp|RVMD - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Revolution Medicines|Quick Liquidity Indicator revmed.com
- earnings and market multiples details:
RVMD - Net Income
Basic company analysis:revmed.com (RVMD)
Core merchandise of Revolution Medicines, Inc.

This metric reconstructs the total value of resources through return on assets, reflecting the balance sheet's immediate market reaction to operating flows and currency revaluations. For precision oncology leader Revolution Medicines (RVMD), this metric demonstrates the efficiency of capital management directed toward the development of RAS inhibitors, allowing for an assessment of the financial basis of innovation via the value of controlled resources.

Key competitors

Total Business Assets ONC|HALO (Halozyme) - Company Total Assets|Cumulative Company Assets Ascentage Pharma Group International (AAPG)|Company Total Assets CGON|Company Total Assets UroGen Pharma Corp (URGN)|Aggregate Company Assets Bicara Therapeutics Inc. BCAX|PSNL: Total Business Assets|Erasca - Company Total Assets|Delcath Systems Inc (DCTH) - Cumulative Company Assets|YMAB: Company Total Assets|Company Assets Aura Corp (AURA)|Aggregate Company Assets Candel Therapeutics Inc.|ARAY: Aggregate Asset Value|Cumulative Company Assets SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics Inc.) - Aggregate Asset Value|Company Total Assets CTOR (Citius Oncology, Inc)|HURA - Cumulative Company Assets|TARA: Cumulative Company Assets|FATE - Company Total Assets|aadibio.com (WHWK) - Aggregate Company Assets|TScan Therapeutics, Inc. - Aggregate Asset Value|CSBR (Champions Oncology Inc) - Company Total Assets|Company Assets XBiotech USA XBIT|Aggregate Company Assets CEL-SCI Corporation (CVM)|OSTX (ostherapies.com) - Aggregate Asset Value|Company Total Assets RADX (Radiopharm Theranostics)|Artiva Biotherapeutics Inc. (ARTV) - Company Assets|ANL: Cumulative Company Assets|VERU: Aggregate Company Assets|Tempest Therapeutics (TPST) - Aggregate Company Assets|Company Assets Xilio Therapeutics (XLO)|Aggregate Company Assets Renovaro Biosciences|Aggregate Company Assets MURA|Cumulative Company Assets KAPA (Kairos Pharma Ltd)|Company Total Assets onkuretherapeutics.com (OKUR)|CytoMed Therapeutics Limited - Cumulative Company Assets|Aggregate Business Assets CRIS (Curis Inc.)|Apollomics Corp - Company Total Assets|Company Total Asset Base Tharimmune Inc THAR|advanbiomed.com (ADVB) - Aggregate Company Assets|Company Assets Genprex Inc (GNPX)|Aggregate Company Assets Calidi Biotherapeutics Inc.|Total Business Assets SBFM (sunshinebiopharma.com)|Cumulative Company Assets XBIO (Xenetic Biosciences)|SLRX (Salarius Pharmaceuticals Inc) - Aggregate Asset Value|Aggregate Company Assets Purple Biotech Corp PPBT|AONC - Cumulative Company Assets|BeiGene, Ltd. - Company Total Assets|Company Assets checkpointtx.com|ELEV: Company Total Assets|Total Business Assets ICAD|IKNA (Ikena Oncology Inc.) - Company Total Assets|Notable Labs Corp (NTBL) - Company Total Asset Base|Company Total Assets VIRX|Cumulative Company Assets morphosys.com MOR|Company Total Assets NAYA (NAYA Biosciences Inc.)|Company Total Asset Base Ascentage Pharma Group International (AAPGV)